Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
J Psychopharmacol ; 26(9): 1218-30, 2012 Sep.
Article in English | MEDLINE | ID: mdl-22767372

ABSTRACT

Clozapine has markedly superior clinical properties compared to other antipsychotic drugs but the side effects of agranulocytosis, weight gain and diabetes limit its use. The reason why clozapine is more effective is not well understood. We studied messenger RNA (mRNA) gene expression in the mouse brain to identify pathways changed by clozapine compared to those changed by haloperidol so that we could identify which changes were specific to clozapine. Data interpretation was performed using an over-representation analysis (ORA) of gene ontology (GO), pathways and gene-by-gene differences. Clozapine significantly changed gene expression in pathways related to neuronal growth and differentiation to a greater extent than haloperidol; including the microtubule-associated protein kinase (MAPK) signalling and GO terms related to axonogenesis and neuroblast proliferation. Several genes implicated genetically or functionally in schizophrenia such as frizzled homolog 3 (FZD3), U2AF homology motif kinase 1 (UHMK1), pericentriolar material 1 (PCM1) and brain-derived neurotrophic factor (BDNF) were changed by clozapine but not by haloperidol. Furthermore, when compared to untreated controls clozapine specifically regulated transcripts related to the glutamate system, microtubule function, presynaptic proteins and pathways associated with synaptic transmission such as clathrin cage assembly. Compared to untreated controls haloperidol modulated expression of neurotoxic and apoptotic responses such as NF-kappa B and caspase pathways, whilst clozapine did not. Pathways involving lipid and carbohydrate metabolism and appetite regulation were also more affected by clozapine than by haloperidol.


Subject(s)
Antipsychotic Agents/pharmacology , Brain/drug effects , Clozapine/pharmacology , Gene Expression Regulation/drug effects , Haloperidol/pharmacology , Neurons/drug effects , Schizophrenia/metabolism , Animals , Antipsychotic Agents/blood , Brain/metabolism , Cell Cycle Proteins/genetics , Cell Cycle Proteins/metabolism , Clozapine/blood , Disease Models, Animal , Gene Expression Profiling , Haloperidol/blood , Male , Mice , Mice, Inbred C57BL , Microtubule Proteins/genetics , Microtubule Proteins/metabolism , Nerve Tissue Proteins/genetics , Nerve Tissue Proteins/metabolism , Neurons/metabolism , Oligonucleotide Array Sequence Analysis , Organ Specificity , Pilot Projects , RNA, Messenger/metabolism , Schizophrenia/drug therapy
2.
Nat Rev Cancer ; 2(3): 201-9, 2002 Mar.
Article in English | MEDLINE | ID: mdl-11990856

ABSTRACT

Pain is the most disruptive influence on the quality of life of cancer patients. Although significant advances are being made in cancer treatment and diagnosis, the basic neurobiology of cancer pain is poorly understood. New insights into these mechanisms are now arising from animal models, and have the potential to fundamentally change the way that cancer pain is controlled.


Subject(s)
Afferent Pathways/physiopathology , Neoplasms/physiopathology , Pain , Humans , Neurons, Afferent/physiology , Nociceptors/physiology
SELECTION OF CITATIONS
SEARCH DETAIL
...